Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression

被引:78
|
作者
Kyle, Robert A. [1 ]
Rajkumar, S. Vincent [1 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN USA
关键词
monoclonal gammopathy of undetermined significance; multiple myeloma; macroglobulinaemia; smouldering multiple myeloma;
D O I
10.1111/j.1365-2141.2007.06873.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a serum monoclonal protein < 30 g/l, < 10% plasma cells in the bone marrow, and absence of end-organ damage (CRAB-hypercalcaemia, renal insufficiency, anaemia, or bone lesions). MGUS is present in 3% of persons > 50 years and in 5% > 70 years of age. The risk of progression to multiple myeloma (MM) or a related disorder is 1% per year. Patients with risk factors consisting of an abnormal serum free light chain ratio, non-immunoglobulin G (IgG) MGUS, and an elevated serum M protein >= 15 g/l had a risk of progression at 20 years of 58%, compared with 37% with two risk factors present, 21% with one risk factor present, and 5% when none of the risk factors were present. Smouldering (asymptomatic) multiple myeloma is characterized by having a serum IgG or IgA monoclonal protein of 30 g/l or higher and/or 10% or more plasma cells in the bone marrow but no evidence of end-organ damage. The cumulative probability of progression to active MM or amyloidosis was 51% at 5 years, 66% at 10 years and 73% at 15 years; the median time to progression was 4.8 years.
引用
收藏
页码:730 / 743
页数:14
相关论文
共 50 条
  • [1] Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma
    Zingone, Adriana
    Kuehl, W. Michael
    SEMINARS IN HEMATOLOGY, 2011, 48 (01) : 4 - 12
  • [2] Monoclonal gammopathy of undetermined significance and multiple myeloma
    Schmalzing, M.
    Tony, H. -P.
    Knop, S.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2017, 76 : 33 - 37
  • [3] Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
    Kyle, Robert A.
    Rajkumar, S. Vincent
    JAMA ONCOLOGY, 2015, 1 (02) : 174 - 175
  • [4] Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
    Cowan, Annie
    Ferrari, Federico
    Freeman, Samuel S.
    Redd, Robert
    El-Khoury, Habib
    Perry, Jacqueline
    Patel, Vidhi
    Kaur, Priya
    Barr, Hadley
    Lee, David J.
    Lightbody, Elizabeth
    Downey, Katelyn
    Argyelan, David
    Theodorakakou, Foteini
    Fotiou, Despina
    Liacos, Christine Ivy
    Kanellias, Nikolaos
    Chavda, Selina J.
    Ainley, Louise
    Sandecka, Viera
    Pospisilova, Lenka
    Minarik, Jiri
    Jungova, Alexandra
    Radocha, Jakub
    Spicka, Ivan
    Nadeem, Omar
    Yong, Kwee
    Hajek, Roman
    Kastritis, Efstathios
    Marinac, Catherine R.
    Dimopoulos, Meletios A.
    Get, Gad
    Trippa, Lorenzo
    Ghobrial, Irene M.
    LANCET HAEMATOLOGY, 2023, 10 (03): : E203 - E212
  • [5] Population attributable fractions for risk factors for the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in the Veteran population
    Wang, Mei
    Ji, Mengmeng
    Schoen, Martin W.
    Sanfilippo, Kristen Marie
    Thomas, Theodore Seth
    Chang, Su-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in a Solid Organ Transplant
    Redfield, Robert R.
    Naji, Ali
    TRANSPLANTATION, 2011, 92 (12) : E65 - E66
  • [7] Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma
    Mailankody, Sham
    Mena, Esther
    Yuan, Constance M.
    Balakumaran, Arun
    Kuehl, W. Michael
    Landgren, Ola
    LEUKEMIA & LYMPHOMA, 2010, 51 (12) : 2159 - 2170
  • [8] Monoclonal Gammopathy of undetermined significance and smoldering multiple myeloma
    Kyle, Robert A.
    Rajkumar, S. Vincent
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (06) : 1093 - +
  • [9] Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
    Robert A. Kyle
    S. Vincent Rajkumar
    Current Hematologic Malignancy Reports, 2010, 5 : 62 - 69
  • [10] Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
    Kyle, Robert A.
    San-Miguel, Jesus F.
    Mateos, Maria-Victoria
    Rajkumar, S. Vincent
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (05) : 775 - +